Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambium BioASX:CMB -4.65%27 1-Year Share Buyback Ratio is -53.20 as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,115 Biotechnology companies, Cambium Bio ranks worse than 78.65% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Cambium Bio's current 1-Year Share Buyback Ratio was -53.20%.
ASX:CMB's 1-Year Share Buyback Ratio is ranked worse than 78.65% of 1115
companies
in the Biotechnology industry
Industry Median: -13.3
vs ASX:CMB: -53.20
Cambium Bio (ASX:CMB) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Cambium Bio 1-Year Share Buyback Ratio Related Terms
ASX:CMB vs VRTX, REGN, RVMD: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Cambium Bio's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Cambium Bio's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -53.20 mean?
Cambium Bio (ASX:CMB) has a 1-Year Share Buyback Ratio of -53.20 as of Dec. 2025. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #877 out of 1115 companies in the Biotechnology industry, placing it in the top 78.7%.
Is Cambium Bio's 1-Year Share Buyback Ratio too high?
Cambium Bio's current 1-Year Share Buyback Ratio is -53.20. Based on the distribution chart, Cambium Bio ranks #877 out of 1115 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's 1-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #877 out of 1115 companies for 1-Year Share Buyback Ratio. This places Cambium Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Cambium Bio and its competitors. Cambium Bio's current 1-Year Share Buyback Ratio is -53.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current 1-Year Share Buyback Ratio of -53.20. The current 1-Year Share Buyback Ratio is -53.20. Cambium Bio's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current 1-Year Share Buyback Ratio is -53.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
27GF Score
Get the complete analysis for ASX:CMB
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
